Clinical Trial

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 8, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-23.
Trial Details
NCT Number NCT06010875
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: The First Affiliated Hospital of Nanchang University
Conditions Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
Enrollment 48 participants
Start Date 2023-11-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-08